Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022 May 24, 2022
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity May 16, 2022
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) May 12, 2022
Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Society of Clinical Oncology (ASCO) April 27, 2022
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares April 18, 2022
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting April 10, 2022